Tenascin is a component of the extracellular matrix that responds rapidly to inflammation or injury. The activity index and chronicity index of immunoglobulin A nephropathy are mainly used to decide whether or not steroid therapy is indicated, but are sometimes difficult to evaluate histologically. We investigated whether tenascin staining of the glomeruli was an indicator of the activity or chronicity indices in patients with immunoglobulin A nephropathy. Tenascin staining was evaluated immunohistochemically in 38 renal specimens, including 32 from patients with immunoglobulin A nephropathy and six from control kidneys, and the extent of staining was scored. Tenascin staining was correlated with the chronicity index (r = 0.643, P < 0.0003) but not with the activity index.
JulianBAWaldoFBRifaiA: IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States?Am J Med1988; 84: 129–132.
2.
NiemirZISteinHNoronhaIL: PDGF and TGF-β. contribute to the natural course of human IgA glomerulonephritis. Kidney Int1995; 48: 1530–1541.
3.
D'AmicoG: Influence of clinical and histological features on actuarial survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: survey of the recent literature. Am J Kidney Dis1992; 20: 315–323.
4.
ChauveauDDrozD: Follow up evaluation of the first patients with IgA nephropathy described at Necker Hospital. IgA nephropathy. The 25th year. Contrib Nephrol1993; 104: 1–5.
5.
AlamartineESabatierJCGuerinC: Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analysis. Am J Kidney Dis1991; 18: 12–19.
6.
D'AmicoGRagniAGandiniE: Typical and atypical natural history of IgA nephropathy in adult patients. Contrib Nephrol1993; 104: 6–13.
7.
FreedmanBISprayBJHeiseER: HLA associations in IgA nephropathy and focal and segmental glomerulonephritis. Am J Kidney Dis1994; 23: 352–357.
8.
AndreoliSPBergsteinJM: Treatment of severe IgA nephropathy in children. Pediatr Nephrol1989; 3: 248–253.
9.
KobayashiYFujiiKHikiY: Steroid therapy of IgA nephropathy: a retrospective study in heavy proteinuric cases. Nephron1988; 48: 12–17.
10.
KobayashiYHikiYFujiiK: Moderately proteinuric IgA nephropathy. Prognostic prediction of individual clinical cases and steroid therapy in progressive cases. Nephron1989; 53: 250–256.
11.
WaldoFBWyattRJKellyDR: Treatment of IgA nephropathy in children: efficacy of alternate-day oral prednisone. Pediatr Nephrol1993; 7: 529–532.
12.
KobayashiYHikiYKokuboT: Steroid therapy during the early stage of progressive IgA nephropathy. Nephron1996; 72: 237–242.
13.
EricksonHPBourdonMA: Tenascin: an extracellular matrix protein prominent in specialized embryonic tissue and tumors. Annu Rev Cell Biol1989; 5: 71–92.
14.
Chiquet-EhrismannRMacKieEJPearsonCA: Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell1986; 47: 131–139.
15.
TruongLDPindurJBarriosR: Tenascin is an important component of the glomerular extracellular matrix in normal and pathologic conditions. Kidney Int1994; 45: 201–210.
16.
AssadLSchwartzMMVirtanenI: Immunolocalization of tenascin and cellular fibronectins in diverse glomerulopathies. Virchows Arch B Cell Pathol1993; 63: 307–316.
17.
ChiquetM: Tenascin: an extracellular matrix protein involved in morphogenesis of epithelial organs. Kidney Int1992; 41: 629–631.
18.
TruongLDFosterSVBarriosR: Tenascin is an ubiquitous extracellular matrix protein of human renal interstitium in normal and pathologic conditions. Nephron1996; 72: 579–586.
19.
TaniguchiYYoriokaNOdaH: Platelet-derived growth factor, interleukin (IL)-1β, IL-6, IL-6R and tumor necrosis factor-α in IgA nephropathy. Nephron1996; 74: 652–660.
20.
TruongLDPindurJFosterSV: Tenascin expression in nephrogenesis and in normal or pathologic features and functional implications. Nephron1996; 72: 499–506.
21.
GouldVEMartinez-LacabeVVirtanenI: Differential distribution of tenascin and cellular fibronectins in acute and chronic renal allograft rejection. Lab Invest1992; 67: 71–79.
22.
WallaceDJGoldfingerDSavageG: Predictive value of clinical, laboratory, pathologic and treatment variables in steroid/immunosuppressive resistant lupus nephritis. J Clin Apheresis1988; 4: 30–34.
23.
JohnsonRJ: Role of cytokines and growth factors in glomerulonephritis: a chance for future therapeutic intervention. Nephron1996; 73: 506–514.
